INTeRCePT 3.0 selected as ZPOC consortium project: A new approach to personalized lymphoma treatment
25.11.2025 17:34
The Zurich Precision Oncology Consortium (ZPOC) is formed by a team that was jointly selected by the Comprehensive Cancer Center Zurich (CCCZ), the Tumor Profiler Center (TPC), and The LOOP Zurich. The project is developing novel models to predict treatment response in lymphoma at an early stage, strengthening precision oncology in Zurich.
The Zurich Precision Oncology Consortium (ZPOC) marks the first structured collaboration between the Comprehensive Cancer Center Zurich (CCCZ), the Tumor Profiler Center (TPC), and The LOOP Zurich, with the shared goal of further strengthening translational cancer research in Zurich. Through this new funding initiative, the three institutions support interdisciplinary collaborators aiming to develop and validate innovative diagnostic and therapeutic approaches for patient-centered precision oncology using state-of-the-art technologies and data science.
All applications underwent a rigorous review process by an international panel of experts evaluating scientific excellence, innovation potential, and clinical relevance. Given the consistently high quality of the submissions, selecting the top-ranked projects proved to be a challenging task.
Ultimately, the international panel recommended INTeRCePT 3.0 for funding—an innovative initiative developing dynamic and personalized risk prediction models to improve lymphoma treatment. By comprehensively analyzing tumor and blood samples and applying advanced computational modeling, the project aims to enable earlier, more targeted therapy decisions and enhance treatment effectiveness.
